name: | Tagraxofusp | |
ATC code: | L01XX67 | route: | intravenous |
compartments: | 2 | |
dosage: | 12 | mg |
volume of distribution: | 6.5 | L |
clearance: | 2.5 | L/h |
other parameters in model implementation |
Tagraxofusp (SL-401) is a fusion protein consisting of human interleukin-3 (IL-3) fused to a truncated diphtheria toxin. It is used for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Tagraxofusp is approved for adult and pediatric patients 2 years and older with BPDCN.
Pharmacokinetics in adult patients with BPDCN, after intravenous infusion. Values primarily reflect population PK analyses from clinical studies.